Advertisement

Inactivation of Hepatitis Viruses (B, Non-A/Non-B) and Retroviruses in Pooled Human Plasma by Means of β-Propiolactone-and UV-Treatment

  • W. Stephan
  • H. Dichtelmüller
  • R. Kotitschke
  • A. M. Prince
  • R. R. Friis
  • H. Bauer
Part of the Developments in Hematology and Immunology book series (DIHI, volume 13)

Abstract

Drugs obtained from human blood, such as coagulation factors and antibody preparations, are manufactured from large pools of plasma; this leads to contamination with viruses from a very wide range of groups.

Keywords

Factor VIII Human Plasma Protein Hepatitis NANB Pool Human Plasma Bilirubin Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    LoGrippo GA, Hartman FW. Chemical and combined methods for plasma sterilization. Bibl. Haematologica 1958; 7: 255–30.Google Scholar
  2. 2.
    Murray R, Oliphant JW, Tripp JT et al. Effect of ultraviolet radiation on the infectivity of icterogenic plasma. JAMA 1955; 157: 8–14.Google Scholar
  3. 3.
    Barker LF, Murray R. Acquisition of hepatitis-associated antigen. Clinical features in young adults. JAMA 1971; 216: 1970–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Pruggmayer D, Stephan W. Gas chromatographic trace analysis of 3-propriolactone in sterilized serum proteins. Vox Sang 1976; 31: 191–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Lissner RW, Pincus JH, Mortelmans K, Tanaka W. On the mutagenicity of 3-propiolactone-treated therapeutic blood products. Lecture and Symposium Abstracts of the Hematology/Transfusion Congress Montreal 1980, No. 478.Google Scholar
  6. 6.
    Kornhuber B. Studie zur Hepatitissicherheit der Serumkonserve Biseko. Biotest-Mitteilungen 1974; 35: 44–5.Google Scholar
  7. 7.
    Kohler-Vajta K, Klose HJ, Frosner G. Klinische Priifung auf Hepatitis-sicherheit eines “hepatitis-sicheren” Prothrombinkomplexes Prothrombinkomplexes in padiatrischem Krankengut. In: JR Kalden u. UD Koenig (Hrsg.) Blutkomponenten und Plasmaersatzmittel. Springer-Verlag Berlin, Heidelberg, New York 1982: 113–6.Google Scholar
  8. 8.
    Prince AM, Stephan W, Brotman B. 3-propiolactone/ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Rev. Infect, Dis. 1983; 5: 92–107.CrossRefGoogle Scholar
  9. 9.
    Heinrich D, Kotitschke R, Berthold H. Clinical evaluation of the hepatitis safety of a 3-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thromb. Res. 1982; 28: 75–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Stephan W, Berthold H. Untersuchungen zur Hepatitissicherheit von sterilisierten Gerinnungsfaktoren aus Humanblut — Eine Schimpansen- studie. In: Kl. Schimpf (Hrsg.) Fibrinogen, Fibrin und Fibrinkleber. Nebenwirkungen der Therapie mit Gerinnungsfaktorenkonzentraten. F.K. Schattauer Verlag Stuttgart, New York 1980: 321–5.Google Scholar
  11. 11.
    Prince AM, Stephan W, Brotman B. Inactivation of non-A, non-B virus infectivity by a 3~propiolactone/ultraviolet irradiation treatment and Aerosil adsorption procedure used for preparation of a stabilized human serum. Vox Sang 1984; 46: 80–5.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • W. Stephan
    • 1
  • H. Dichtelmüller
    • 1
  • R. Kotitschke
    • 1
  • A. M. Prince
    • 2
  • R. R. Friis
    • 3
  • H. Bauer
    • 3
  1. 1.Biotest PharmaFrankfurt/MainWest Germany
  2. 2.The New York Blood CenterNew YorkUSA
  3. 3.Justus Liebig UniversityGiessenWest Germany

Personalised recommendations